ADMA BIOLOGICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ADMA BIOLOGICS, INC. (ADMA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was -$13.32M.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.82M.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $130.00K, a 96.79% decline from fiscal 2022.
- ADMA BIOLOGICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.05M, a 13.90% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$13.32M derived: sum of 2 quarters · filed 2026-02-25 | $1.82M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$13.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.82M 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $15.15M 10-Q · filed 2026-08-05 | $1.24M 10-Q · filed 2025-08-06 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||||
| 2023-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $130.00K derived: sum of 2 quarters · filed 2026-02-25 | $130.00K 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||||
| 2022-12-31 | $387.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $387.11K derived: sum of 2 quarters · filed 2025-03-18 | $4.05M derived: sum of 3 quarters · filed 2025-03-18 | $4.05M 10-K · filed 2025-03-18 | $4.05M 10-K · filed 2023-03-23 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.66M derived: sum of 2 quarters · filed 2023-11-08 | $3.66M 10-Q · filed 2023-11-08 | $4.37M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.66M 10-Q · filed 2023-08-09 | $4.37M derived: sum of 3 quarters · filed 2024-02-28 | $4.37M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | $709.13K derived: sum of 2 quarters · filed 2024-02-28 | $709.13K derived: sum of 3 quarters · filed 2024-02-28 | $1.48M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $709.13K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $709.13K derived: sum of 2 quarters · filed 2024-02-28 | $1.48M derived: sum of 3 quarters · filed 2024-02-28 | $3.55M 10-K · filed 2024-02-28 | $3.55M 10-K · filed 2022-03-24 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $771.25K derived: sum of 2 quarters · filed 2022-11-09 | $2.84M 10-Q · filed 2022-11-09 | $4.44M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $771.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.84M 10-Q · filed 2022-08-10 | $4.44M derived: sum of 3 quarters · filed 2022-08-10 | $4.45M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $2.07M 10-Q · filed 2022-05-11 | $3.66M derived: sum of 2 quarters · filed 2022-05-11 | $3.68M derived: sum of 3 quarters · filed 2022-05-11 | $4.86M derived: sum of 4 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $1.61M derived: sum of 2 quarters · filed 2022-03-24 | $2.78M derived: sum of 3 quarters · filed 2022-03-24 | $3.33M 10-K · filed 2022-03-24 | $1.42M 10-K · filed 2021-03-25 | |
| 2020-09-30 | $14.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.19M derived: sum of 2 quarters · filed 2021-11-10 | $1.74M 10-Q · filed 2021-11-10 | $3.65M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.72M 10-Q · filed 2021-08-11 | $3.63M derived: sum of 3 quarters · filed 2021-08-11 | $3.63M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $545.63K 10-Q · filed 2020-05-06 | $2.45M derived: sum of 2 quarters · filed 2021-03-25 | $2.45M derived: sum of 3 quarters · filed 2021-03-25 | $2.47M derived: sum of 4 quarters · filed 2021-03-25 | ||
| 2019-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.91M derived: sum of 2 quarters · filed 2021-03-25 | $1.93M derived: sum of 3 quarters · filed 2021-03-25 | $3.33M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $17.39K derived: sum of 2 quarters · filed 2020-11-05 | $1.42M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $17.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.42M 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | $1.40M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |